Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...
Rheumatology Advisor5d
Week 52 Data Show Inebilizumab Continues to Benefit in AChR+ Myasthenia Gravis
Treatment with inebilizumab was associated with continued improvement in patients with AChR+ generalized myasthenia gravis, according to 52-week results from the MINT trial.
STAT3d
Immunovant and Roivant report success in autoimmune drug’s Phase 3 trial
The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.
MedPage Today on MSN4d
Myasthenia Gravis Antibody Types
Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...
pharmaphorum1d
UCB bags FDA approval for second myasthenia gravis drug
Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...
Clinical Trials Arena on MSN3d
Immunovant will not seek approval for MG therapy, despite hitting endpoints
The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
Indiatimes3d
Graviss Hospitality Share Price
Graviss Hospitality Ltd., incorporated in the year 1959, is a Small Cap company (having a market cap of Rs 278.69 Crore) operating in Tourism & Hospitality sector. Graviss Hospitality Ltd. key ...